Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study

Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study

Abstract Aims Sodium‐glucose cotransporter type 2 inhibitors (SGLT‐2i) represent a unique class of anti‐hyperglycaemic agents for type 2 diabetes mellitus that selectively inhibit renal glucose reabsorption, thereby increasing urinary excretion of glucose. Several studies have demonstrated the cardi...

Description complète

Détails bibliographiques
Auteurs principaux: Michele Correale, Elena‐Laura Antohi, Riccardo M. Inciardi, Pietro Mazzeo, Stefano Coiro, Shiro Ishihara, Renata Petroni, Francesco Monitillo, Marta Leone, Marco Triggiani, Chaudhry M.S. Sarwar, Hans‐Dirk Dungen, Khawaja M. Talha, Natale D. Brunetti, Javed Butler, Savina Nodari, Master Program Group on Drug Development for Heart Failure
Format: Article
Langue:English
Publié: Wiley 2023-06-01
Collection:ESC Heart Failure
Sujets:
Sodium‐glucose cotransporter type 2 inhibitors (SGLT‐2i)
Heart failure (HF)
Cardiac structure and function
Echocardiography
Accès en ligne:https://doi.org/10.1002/ehf2.14331

Internet

https://doi.org/10.1002/ehf2.14331

Documents similaires